Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026

Key Takeaways

• Acurx DNA pol IIIC inhibitors demonstrated systemic antibacterial activity against MRSA while preserving gut microbiome in preclinical studies
• The compounds achieved therapeutic plasma levels and reduced MRSA tissue burden in neutropenic mice models
• Results will be presented at ESCMID Global 2026, potentially advancing a new class of antibiotics with reduced microbiome disruption

---

Acurx Pharmaceuticals Presents Breakthrough Antibiotic Data

Acurx Pharmaceuticals announced it will present scientific poster data at ESCMID Global 2026 demonstrating that its novel DNA pol IIIC inhibitors offer an unexpected benefit: preserving gut microbiome while maintaining effective antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).

Study Design and Methodology

The preclinical study utilized neutropenic CD-1 mice infected intramuscularly with MRSA. Researchers administered three different Acurx DNA pol IIIC inhibitors orally, comparing results against linezolid treatment and placebo controls. This methodology allowed for direct comparison with an established antibiotic standard.

Clinical Significance of Microbiome Preservation

The preservation of gut microbiome represents a significant advancement in antibiotic development. Traditional antibiotics often disrupt beneficial bacteria, leading to complications including Clostridioides difficile infections, antibiotic-associated diarrhea, and long-term microbiome imbalances. Acurx’s compounds appear to target pathogenic bacteria while sparing beneficial microorganisms.

Therapeutic Efficacy Results

The study demonstrated that Acurx compounds achieved potentially therapeutic plasma levels, indicating proper systemic distribution. More importantly, the treatments successfully reduced MRSA tissue burden in infected animals, proving antibacterial efficacy comparable to existing treatments.

Market Impact and Future Implications

MRSA infections affect approximately 80,000 Americans annually, with limited treatment options due to antibiotic resistance. The development of antibiotics that maintain efficacy while preserving microbiome health could address a critical unmet medical need and potentially reduce healthcare costs associated with antibiotic-related complications.

Next Steps

The ESCMID Global 2026 presentation will provide the scientific community with detailed data on this novel mechanism of action. Success in these preclinical studies may support advancement to human clinical trials, bringing this innovative antibiotic class closer to patients facing serious MRSA infections.

---

Frequently Asked Questions

What makes Acurx DNA pol IIIC inhibitors different from existing antibiotics?

These inhibitors target a specific bacterial enzyme (DNA polymerase IIIC) while preserving beneficial gut bacteria, unlike traditional antibiotics that often disrupt the entire microbiome.

When will these antibiotics be available to patients?

The compounds are currently in preclinical testing. If successful, they would need to complete human clinical trials, which typically take several years before potential FDA approval.

How effective are these drugs compared to linezolid for MRSA treatment?

Preclinical data shows comparable efficacy to linezolid in reducing MRSA tissue burden, with the added benefit of microbiome preservation, though human trials are needed to confirm clinical effectiveness.